#South Korea #Samsung Biologics #Incheon #Biomanufacturing #ExellenS™

Samsung Biologics Reveals ExellenS™ Framework

Incheon, South Korea, has become the epicenter of a revolutionary shift in biomanufacturing, as Samsung Biologics (KRX 207940.KS) unveils an innovative manufacturing framework named ExellenS™. This new framework is strategically designed to optimize facility designs, equipment, and processes across all sites within the company’s biomanufacturing network. By ensuring consistency in operations, ExellenS™ delivers a standardization that translates into speed and efficiency, making it a significant step forward for contract development and manufacturing organization (CDMO) services.

The Essence of ExellenS™

ExellenS™ represents Samsung Biologics’ commitment to operational excellence, focusing on four foundational pillars: client satisfaction, operations efficiency, quality assurance, and workforce expertise. These pillars guide the company in maintaining its competitive edge globally. John Rim, President and CEO of Samsung Biologics, states, "ExellenS™ reflects our established and unmatched competence in on-time project delivery and manufacturing excellence." The framework promises to set a new standard for scalability and optimization in biomanufacturing operations.

The introduction of ExellenS™ entails the integration of Functional Design Specifications (FDS) throughout all production facilities, promoting the use of standardized bioreactor configurations and automation systems. This step is crucial as it allows each facility to achieve the same level of operational precision, ensuring that every manufactured product meets the highest standards of quality.

Accelerating Speed to Market

A critical aspect of ExellenS™ is its ability to accelerate the time it takes for biopharmaceuticals to reach the market. By applying consistent operational practices across all plants, the framework enhances global regulatory preparedness for clients, reducing risks associated with compliance and minimizing the need for extensive changeovers during production. This streamlined approach not only promotes agile tech transfers but also facilitates quicker scaling and product launches, giving clients the competitive edge they need in a complex global market.

Resilience Through Standardization

In today’s volatile market environment, resilience is key to success. The ExellenS™ framework promotes supply chain continuity by enabling dual-sourcing and production across multiple plants. This strategic approach enhances Samsung Biologics' ability to navigate potential disruptions while ensuring that clients can maintain uninterrupted access to essential therapies. Furthermore, the integration of a unified digital platform aids in managing challenges with unparalleled agility, thereby reinforcing the company's commitment to high-quality service delivery.

Samsung Biologics also emphasizes the diminishment of variability between production facilities and processes. By replicating standard procedures and employing universal equipment specifications, the company aims to enhance rapid technology transfers and seamless scalability, ensuring that clients receive a reliable product regardless of where it is manufactured.

Looking Ahead

As industry demands evolve, so does Samsung Biologics. The company is currently enhancing its manufacturing capacity, projecting a total of 784,000 liters across five operational plants. Following the recent operational launch of its newest facility, Plant 5 at Bio Campus II, Samsung Biologics is slated to increase its capabilities by 2032. This growth is aligned with the company’s goal to augment its portfolio, ensuring clients can meet increasing global healthcare demands with ease and flexibility.

“The ExellenS™ framework epitomizes our mission to assist clients in improving and prolonging lives,” Rim added. This innovative approach encompasses years of investment and dedication, providing clients the confidence and adaptability necessary to advance their therapies and bring hope to patients around the world.

About Samsung Biologics

As a leading CDMO, Samsung Biologics offers a comprehensive suite of integrated services that span from late-stage discovery to commercial manufacturing. The company's expertise encompasses various modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates (ADCs), and mRNA therapeutics. Committed to operational excellence, Samsung Biologics continues to prioritize innovative capabilities and sustainable practices, ensuring its place as a trusted partner in the healthcare sector.